

IN THE CLAIMS:

1. (Amended) A pharmaceutical composition for eliminating or reducing the number of unwanted CD3 and/or CD7 positive cells, said pharmaceutical composition comprising: a mixture [of at least] comprising a first molecule specifically recognizing CD3 or CD7, and [at least]

A second molecule specifically recognizing another ligand receptor associated with the surface of [such an] said unwanted [cell whereby] CD3 and/or CD7 positive cells, wherein at least one of the [specifically recognizing] first and second molecules [is provided with] includes a toxic moiety.

2. (Amended) [A] The pharmaceutical composition [according to] of claim 1, [whereby] wherein said first molecule specifically recognizes CD3 and said second molecule specifically recognizes CD7.

3. (Amended) [A] The pharmaceutical composition [according to] of claim 1 [or 2], wherein said first molecule is an antibody, or a fragment or a derivative thereof.

4. (Amended) [A] The pharmaceutical composition [according to any one of claims 1-3] of claim 1, wherein said second molecule is an antibody, or a fragment or a derivative thereof.

5. (Amended) [A] The pharmaceutical composition [according to any one of claims 1-4] of claim 1, wherein said toxic moiety is ricin.

6. (Amended) [A] The pharmaceutical composition [according to any one] of claim 5, wherein said ricin is deglycosylated ricin A.

7. (Amended) [A] The pharmaceutical composition [according to any one of claims 1-6] of claim 1, wherein said toxic moiety is chemically linked to said molecule specifically

recognizing CD3, CD7 or another ligand receptor associated with the surface of [such an unwanted] said unwanted CD3 and/or CD7 positive cell.

B3 8. (Amended) [A] The pharmaceutical composition [according to any one of claims 1-7] of claim 1, wherein at least two molecules specifically recognizing different receptors are provided with toxic moieties, which may be the same or different toxic moieties.

9. (Amended) [A] The pharmaceutical composition [according to any one of claims 1-8] of claim 1, further comprising [at least one further] a third molecule specifically recognizing CD5, CD2, CD4, CD8 or an IL-2 receptor.

10. (Amended) [A] The pharmaceutical composition [according to] of claim 1, wherein said first molecule is a gamma2B IgG antibody or a derivative thereof, which first molecule recognizes CD3.

11. (Amended) [A] The pharmaceutical composition [according to anyone of the afore going claims] of claim 5, which comprises at least the equivalent [dosis] dose of 25 micrograms of Ricin A per square meter of body surface of a subject to which the composition is to be administered.

12. (Amended) [A] The pharmaceutical composition [according to] of claim 11, comprising at least the equivalent [dosis] dose of 100 micrograms of Ricin A per square meter of the subject's body surface.

13. (Amended) [A] The pharmaceutical composition of claim 11 comprising at most the equivalent [dosis] dose of 25 mg of Ricin A per square meter of the subject's body surface.

Please cancel claim 14 without prejudice or disclaimer.

15. (Amended) [Use of a] A method of treating a disease state in a subject believed to be suffering therefrom, said method comprising administering to the subject an amount of a

85  
A2  
10/1/0

pharmaceutical composition [according to anyone of the afore going claims in the preparation of a medicament for the treatment of] said disease states selected from the group of disease states comprising Graft vs. Host disease, Graft rejections, T-cell leukemias, T-cell lymphomas, [or] other CD3 and/or CD7 positive malignancies, autoimmune diseases, [or] and infectious immune diseases [such as HIV-infection], said pharmaceutical composition comprising:

a mixture comprising a first molecule specifically recognizing CD3 or CD7, and  
a second molecule specifically recognizing another ligand receptor associated with  
the surface of unwanted CD3 and/or CD7 positive cells, wherein at least one of the first and  
second molecules includes a toxic moiety.

Please cancel claims 16 and 17 without prejudice or disclaimer.

Please add the following new claims:

sub 86

18. The pharmaceutical composition of claim 2, wherein said first molecule is an antibody, or a fragment or a derivative thereof.

19. The pharmaceutical composition of claim 18, wherein said second molecule is an antibody, or a fragment or a derivative thereof.

A3

20. The pharmaceutical composition of claim 19, wherein said toxic moiety is deglycosylated ricin A.

sub 87

21. The pharmaceutical composition claim 19, wherein said toxic moiety is chemically linked to said molecule specifically recognizing CD3, CD7 or another ligand receptor associated with the surface of unwanted CD3 and/or CD7 positive unwanted cell.

22. The pharmaceutical composition claim 21, wherein at least two molecules specifically recognizing different receptors are provided with toxic moieties, which may be the same or different toxic moieties.